
AIMT
Healthcare · Biotechnology · $2.26B market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Sep 30, 2020
EPS trend, 90 days to now · +100.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 1 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Jul 30, 2020 | Time not confirmed | -1.09 | -1.06 | +2.8% |
| May 11, 2020 | Time not confirmed | -1.18 | -1.34 | -13.6% |
| Feb 27, 2020 | Time not confirmed | -1.06 | -1.06 | 0.0% |
| Nov 6, 2019 | Time not confirmed | -1.03 | -1.03 | 0.0% |
| Aug 8, 2019 | Time not confirmed | -0.94 | -1.01 | -7.4% |
| May 8, 2019 | Time not confirmed | -0.97 | -0.87 | +10.3% |
| Feb 28, 2019 | Time not confirmed | -0.91 | -0.95 | -4.4% |
| Nov 8, 2018 | Time not confirmed | -0.90 | -0.89 | +1.1% |
| Aug 8, 2018 | Time not confirmed | -0.86 | -0.91 | -5.8% |
| May 8, 2018 | Time not confirmed | -0.71 | -0.92 | -29.6% |
| Feb 20, 2018 | Time not confirmed | -0.73 | -0.81 | -11.0% |
Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy. The company also engages in the…